Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

43P - Prognostic impact of the tumor immune microenvironment in adrenocortical cancer


06 Mar 2023


Cocktail & Poster Display session


Nano Pachuashvili


Annals of Oncology (2023) 8 (1suppl_2): 100903-100903. 10.1016/esmoop/esmoop100903


N. Pachuashvili1, L. Urusova2

Author affiliations

  • 1 Institute Of Clinical Morphology And Digital Pathology, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 - Moscow/RU
  • 2 Department Of Fundamental Pathomorphology, Endocrinology Research Centre, 117036 - Moscow/RU


This content is available to ESMO members and event participants.

Abstract 43P


Adrenocortical carcinoma (ACC) is an uncommon endocrine malignancy, usually characterized by a late detection, aggressive clinical course, and poor outcome. The tumor microenvironment (TME) which includes infiltrating immune cells plays a critical role in tumor growth, survival, and prognosis in cancer patients. The presence of tumor-infiltrating immune cells (TIIC) affect the clinical benefit from novel strategies of immunological checkpoint blockade. Anti-immune pathways like PD-L1 are used by the tumor to overcome immune system and they serve as immunotherapy targets.


The study included tumor tissue samples from 75 patients with ACC, which treated at the Endocrinology Research Centre (Russia, Moscow) between 2010 and 2022: 47 cases of conventional (62,7%), 18 cases of oncocytic (24%), and 9 cases of myxoid (12%) and 1 case of sarcomatoid (1,3%) variants of ACC. Immunohistochemical analysis of tumor tissue sections was carried out according to the standard technique with a peroxidase detection system with DAB on an automatic Leica BOND III IHC staining system using Leica reagents and protocols. Each of the 75 patients underwent histological diagnostics and a series of immunohistochemical stains for the markers of the main immune cell subsets: CD45, CD3, CD4, CD8, and CD68. The impact of PD-L1 expression and the number of TIIC considering the intratumoral and stromal distribution on pathological characteristics and clinical outcomes were analysed.


The number of СD45+ immune cells in tumor parenchyma and stroma was 189 and 268 cells/mm2, respectively. However, the number of immune cells from all the analyzed populations in tumor parenchyma was higher in oncocytic compared to conventional ACC cases. The analysis of the relationship of survival with the studied factors showed that the overall survival and progression-free survival between conventional and oncocytic histological variants differ significantly. The differences in survival between conventional and oncocytic histological variants of ACC were statistically significant (p-value < 0.05). PD-L1 expression does not affect prognosis.


Rich T-lymphocyte response is a good prognostic factor in ACC. The study of TIIL subpopulations can be used to predict ACC outcomes.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.